GCA
ABBV icon

Gradient Capital Advisors’s AbbVie ABBV Stock Holding History

Gradient Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$355K Buy
1,411
+1
+0.1% +$215 0.08% 133
2026
Q1 		$307K Buy
1,410
+2
+0.1% +$444 0.08% 135
2025
Q4 		$322K Buy
1,408
+1
+0.1% +$228 0.08% 131
2025
Q3 		$326K Buy
1,407
+28
+2% +$5.7K 0.09% 126
2025
Q2 		$256K Buy
1,379
+43
+3% +$7.99K 0.08% 141
2025
Q1 		$280K Buy
1,336
+10
+0.8% +$1.94K 0.09% 131
2024
Q4 		$236K Buy
1,326
+1
+0.1% +$184 0.08% 143
2024
Q3 		$262K Buy
1,325
+2
+0.2% +$373 0.09% 133
2024
Q2 		$227K Buy
1,323
+1
+0.1% +$166 0.08% 134
2024
Q1 		$241K Buy
1,322
+29
+2% +$5K 0.09% 129
2023
Q4 		$200K Buy
+1,293
New +$189K 0.08% 140

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Gradient Capital Advisors's ABBV Position: Q2 2026 in Review

Gradient Capital Advisors increased its AbbVie (ABBV) stake by 0.07% in Q2 2026, buying an estimated $215 and bringing the position to 1,411 shares worth $355K. The position accounts for 0.08% of the portfolio, ranked #133.

Gradient Capital Advisors first reported a position in ABBV in Q4 2023 and has held it in 11 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Gradient Capital Advisors held 1,411 shares of AbbVie worth $355K as of Q2 2026.
  • Gradient Capital Advisors bought 1 AbbVie share in Q2 2026, an estimated $215.
  • AbbVie made up 0.08% of Gradient Capital Advisors's portfolio in Q2 2026, its #133 holding.
  • Gradient Capital Advisors first reported a position in AbbVie in Q4 2023 and has held it in 11 quarters since.
  • 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Gradient Capital Advisors's 13F filing for Q2 2026, filed 13 Jul 2026.